446 related articles for article (PubMed ID: 22739667)
1. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
López RL; del Muro XG
Anticancer Drugs; 2012 Jun; 23 Suppl():S3-6. PubMed ID: 22739667
[TBL] [Abstract][Full Text] [Related]
2. Tumor rupture exposes the patient to an increased risk of relapse, regardless of the size and number of mitoses.
Quintero CB; Cubedo R
Anticancer Drugs; 2012 Jun; 23 Suppl():S1-2. PubMed ID: 22739664
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
[TBL] [Abstract][Full Text] [Related]
4. New fronts in the adjuvant treatment of GIST.
Reichardt P; Joensuu H; Blay JY
Cancer Chemother Pharmacol; 2013 Oct; 72(4):715-23. PubMed ID: 23934322
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant imatinib therapy for gastrointestinal stromal tumors.
Pisters PW; Colombo C
J Surg Oncol; 2011 Dec; 104(8):896-900. PubMed ID: 22069174
[TBL] [Abstract][Full Text] [Related]
6. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
Kang YK; Kang BW; Im SA; Lee JL; Park SR; Kang WK; Chang HM; Kim TW; Oh DY; Jung KH; Ryu MH
Cancer Chemother Pharmacol; 2013 Jan; 71(1):43-51. PubMed ID: 23053257
[TBL] [Abstract][Full Text] [Related]
7. Recurrence risk after resection of gastrointestinal stromal tumors: size is not all that matters... The consequences of tumor rupture.
Han D; Deneve J; Gonzalez RJ
Am Surg; 2012 Jan; 78(1):74-9. PubMed ID: 22273319
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.
Jiang WZ; Guan GX; Lu HS; Yang YH; Kang DY; Huang HG
J Surg Oncol; 2011 Dec; 104(7):760-4. PubMed ID: 21713778
[TBL] [Abstract][Full Text] [Related]
9. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
Tielen R; Verhoef C; van Coevorden F; Gelderblom H; Sleijfer S; Hartgrink HH; Bonenkamp JJ; van der Graaf WT; de Wilt JH
Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087
[TBL] [Abstract][Full Text] [Related]
10. [Imatinib in the GIST therapy: ten years later].
Lopez M
Clin Ter; 2011; 162(6):563-73. PubMed ID: 22262331
[TBL] [Abstract][Full Text] [Related]
11. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant imatinib for gastrointestinal stromal tumors: the current situation and problems.
Zhong JH; Ma L; Li LQ; Ru HM; Zhao YN
Scand J Gastroenterol; 2011 Jun; 46(6):645-51. PubMed ID: 21271901
[TBL] [Abstract][Full Text] [Related]
13. Patient with high-risk GIST not associated with c-KIT mutations: same benefit from adjuvant therapy?
Izquierdo ME; Bonastre MT
Anticancer Drugs; 2012 Jun; 23 Suppl():S7-9. PubMed ID: 22739668
[TBL] [Abstract][Full Text] [Related]
14. Congestive heart failure in a 77-year-old woman receiving adjuvant treatment with imatinib for a large gastric gastrointestinal stromal tumour.
Pulido EG; Riquelme A; Ballesteros J; Vaz MÁ
Anticancer Drugs; 2012 Jun; 23 Suppl():S15-7. PubMed ID: 22739666
[TBL] [Abstract][Full Text] [Related]
15. [Morphological characteristics and prognostic criteria for gastrointestinal stromal tumors].
Tsyganova IV; Anurova OA; Mazurenko NN
Arkh Patol; 2011; 73(6):37-42. PubMed ID: 22379899
[TBL] [Abstract][Full Text] [Related]
16. [New prospective on adjuvant treatment for gastrointestinal stromal tumors].
Pan ZZ; Wu XJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):212-5. PubMed ID: 23536337
[TBL] [Abstract][Full Text] [Related]
17. Practical management of imatinib in gastrointestinal stromal tumors.
Barnes T; Reinke D
Clin J Oncol Nurs; 2011 Oct; 15(5):533-45. PubMed ID: 21951740
[TBL] [Abstract][Full Text] [Related]
18. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
Andtbacka RH; Ng CS; Scaife CL; Cormier JN; Hunt KK; Pisters PW; Pollock RE; Benjamin RS; Burgess MA; Chen LL; Trent J; Patel SR; Raymond K; Feig BW
Ann Surg Oncol; 2007 Jan; 14(1):14-24. PubMed ID: 17072676
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
Li J; Dang YZ; Gao J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):216-20. PubMed ID: 23536338
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal stromal tumours.
Connolly EM; Gaffney E; Reynolds JV
Br J Surg; 2003 Oct; 90(10):1178-86. PubMed ID: 14515284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
